How does Wegovy compare to Saxenda?

Both are GLP-1 agonists from Novo Nordisk. Wegovy (semaglutide, weekly) produces ~15% mean weight loss; Saxenda (liraglutide, daily) produces ~6-8%. Wegovy is also cheaper per kg-lost, more convenient, and has cardiovascular outcome data (SELECT trial). Saxenda was first approved for adolescents (2020); Wegovy followed in 2022 — both are available for ages 12-17.

Kaiser Permanente appeal guide

Kaiser Permanente Saxenda coverage appeal

Kaiser Permanente uses specific clinical-policy criteria for Saxenda. Most denials come from undocumented BMI history or missing step-therapy notes. Here is how to address both.

Kaiser Permanente prior authorization criteria for Saxenda

Internal Kaiser formulary committee decision — varies by region
BMI documentation + 6-month structured weight-loss program

Kaiser Permanente Saxenda policy bulletin

Step-by-step appeal flow

1
Pull your carrier policy bulletin
Kaiser Permanente publishes its Saxenda coverage criteria. Read it first — every successful appeal cites it back to the reviewer.
2
Document your medical necessity
Internal Kaiser formulary committee decision — varies by region BMI documentation + 6-month structured weight-loss program
3
Have your prescriber submit the PA
Most Kaiser Permanente PAs go through CoverMyMeds or the carrier portal. Your prescriber attaches BMI history, comorbidities (with ICD-10 codes), lifestyle program participation, and prior weight-loss attempts.
4
If denied — file the appeal within 60 days
Kaiser is integrated (insurer + prescriber + pharmacy) — appeals go through internal grievance department, not pharmacy benefit manager. Use the regional grievance form.
5
Submit external review if internal appeals fail
After two internal appeals, you can request external review through your state insurance commissioner. ERISA plans go through the federal external-review process.

Letter template

Customizable Kaiser Permanente appeal letter

We provide a generic medical-necessity letter generator. Customize with the Kaiser Permanente-specific framing above for highest first-pass success.

Generate appeal letter

Common questions readers ask

How does Wegovy compare to Saxenda?: Both are GLP-1 agonists from Novo Nordisk. Wegovy (semaglutide, weekly) produces ~15% mean weight loss; Saxenda (liraglutide, daily) produces ~6-8%. Wegovy is also cheaper per kg-lost, more convenient, and has cardiovascular outcome data (SELECT trial). Saxenda was first approved for adolescents (2020); Wegovy followed in 2022 — both are available for ages 12-17.

Editorial information based on published Kaiser Permanente coverage policies as of 2026. Your specific plan benefits may differ — confirm with your insurance card’s member services number. Not legal advice.